236 related articles for article (PubMed ID: 24700342)
1. Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.
Werner JM; Serti E; Chepa-Lotrea X; Stoltzfus J; Ahlenstiel G; Noureddin M; Feld JJ; Liang TJ; Rotman Y; Rehermann B
Hepatology; 2014 Oct; 60(4):1160-9. PubMed ID: 24700342
[TBL] [Abstract][Full Text] [Related]
2. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.
Edlich B; Ahlenstiel G; Zabaleta Azpiroz A; Stoltzfus J; Noureddin M; Serti E; Feld JJ; Liang TJ; Rotman Y; Rehermann B
Hepatology; 2012 Jan; 55(1):39-48. PubMed ID: 21898483
[TBL] [Abstract][Full Text] [Related]
3. PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.
Markova AA; Mihm U; Schlaphoff V; Lunemann S; Filmann N; Bremer B; Berg T; Sarrazin C; Zeuzem S; Manns MP; Cornberg M; Herrmann E; Wedemeyer H
PLoS One; 2014; 9(4):e94512. PubMed ID: 24751903
[TBL] [Abstract][Full Text] [Related]
4. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Serti E; Park H; Keane M; O'Keefe AC; Rivera E; Liang TJ; Ghany M; Rehermann B
Gut; 2017 Apr; 66(4):724-735. PubMed ID: 26733671
[TBL] [Abstract][Full Text] [Related]
5. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.
Ahlenstiel G; Edlich B; Hogdal LJ; Rotman Y; Noureddin M; Feld JJ; Holz LE; Titerence RH; Liang TJ; Rehermann B
Gastroenterology; 2011 Oct; 141(4):1231-9, 1239.e1-2. PubMed ID: 21741920
[TBL] [Abstract][Full Text] [Related]
6. Ribavirin Improves NK Cell IFNγ Response During Sofosbuvir-based DAA Therapy in HCV-infected Liver Transplant Recipients.
Adenugba A; Hornung M; Weigand K; Peschel G; Junger H; Kupke P; Lang H; Marquardt JU; Zimmermann T; Geissler EK; Schlitt HJ; Werner JM
Transplantation; 2021 Oct; 105(10):2226-2238. PubMed ID: 33587435
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
Wang T; Blatt LM; Seiwert SD
J Interferon Cytokine Res; 2006 Jul; 26(7):473-83. PubMed ID: 16800786
[TBL] [Abstract][Full Text] [Related]
8. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
Pár G; Berki T; Pálinkás L; Balogh P; Szereday L; Halász M; Szekeres-Barthó J; Miseta A; Hegedus G; Mózsik G; Hunyady B; Pár A
Orv Hetil; 2006 Apr; 147(13):591-600. PubMed ID: 16623441
[TBL] [Abstract][Full Text] [Related]
9. Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin.
Conti F; Vukotic R; Lorenzini S; Riili A; Cursaro C; Scuteri A; Loggi E; Galli S; Furlini G; Bernardi M; Andreone P
Ann Hepatol; 2014; 13(2):196-203. PubMed ID: 24552861
[TBL] [Abstract][Full Text] [Related]
10. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
[TBL] [Abstract][Full Text] [Related]
11. Natural cytotoxicity receptor-dependent natural killer cytolytic activity directed at hepatitis C Virus (HCV) is associated with liver inflammation, African American race, IL28B genotype, and response to pegylated interferon/ribavirin therapy in chronic HCV infection.
Meng Q; Rani MR; Sugalski JM; Judge CJ; Phat S; Rodriguez B; Blanton RE; Anthony DD
J Infect Dis; 2014 May; 209(10):1591-601. PubMed ID: 24302757
[TBL] [Abstract][Full Text] [Related]
12. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection.
Miyagi T; Takehara T; Nishio K; Shimizu S; Kohga K; Li W; Tatsumi T; Hiramatsu N; Kanto T; Hayashi N
J Hepatol; 2010 Sep; 53(3):424-30. PubMed ID: 20554341
[TBL] [Abstract][Full Text] [Related]
13. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.
Dill MT; Makowska Z; Duong FHT; Merkofer F; Filipowicz M; Baumert TF; Tornillo L; Terracciano L; Heim MH
Gastroenterology; 2012 Sep; 143(3):777-786.e6. PubMed ID: 22677194
[TBL] [Abstract][Full Text] [Related]
14. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
15. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
[TBL] [Abstract][Full Text] [Related]
16. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
[TBL] [Abstract][Full Text] [Related]
17. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
20. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.
Rotman Y; Noureddin M; Feld JJ; Guedj J; Witthaus M; Han H; Park YJ; Park SH; Heller T; Ghany MG; Doo E; Koh C; Abdalla A; Gara N; Sarkar S; Thomas E; Ahlenstiel G; Edlich B; Titerence R; Hogdal L; Rehermann B; Dahari H; Perelson AS; Hoofnagle JH; Liang TJ
Gut; 2014 Jan; 63(1):161-9. PubMed ID: 23396509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
